¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"relative scotoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative risk
    »ó´ëÀ§Çèµµ
  • relative risk ratio
    »ó´ëÀ§Çèºñ
  • relative sterility
    »ó´ëÀûºÒÀÓ
  • relative survival rate
    »ó´ë»ýÁ¸À²
  • relative valvular insufficiency
    »ó´ëÀûÆÇ¸·±â´ÉºÎÀü
  • resource based relative value scale
    ÀÚ¿ø±âÁØ»ó´ë°¡Ä¡µî±Þ
  • annular scotoma
    °í¸®¾ÏÁ¡, À±»ó¾ÏÁ¡
  • arcuate scotoma
    Ȱ¾ÏÁ¡, Ȱ²Ã¾ÏÁ¡
  • absolute scotoma
    Àý´ë¾ÏÁ¡
  • cecocentral scotoma
    ÁÖ½ÃÁ¡¸ÍÁ¡¾ÏÁ¡, ¸ÍÁ¡Á߽ɾÏÁ¡
  • central scotoma
    Á߽ɾÏÁ¡
  • centrocecal scotoma
    ÁÖ½ÃÁ¡¸ÍÁ¡¾ÏÁ¡, ¸ÍÁ¡Á߽ɾÏÁ¡
  • double arcuate scotoma
    ÀÌÁßȰ¾ÏÁ¡
  • flittering scotoma
    ¼¶±¤¾ÏÁ¡
  • frame scotoma
    ¾È°æÅ×¾ÏÁ¡
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • pericentral scotoma
    Áß½ÉÁÖÀ§¾ÏÁ¡
  • peripheral scotoma
    ÁÖº¯¾ÏÁ¡
  • physiological scotoma
    »ý¸®¾ÏÁ¡
  • positive scotoma
    ¾ç¼º¾ÏÁ¡, ÀνľÏÁ¡
  • quadrantic scotoma
    »çºÐ¸Í¾ÏÁ¡
  • ring scotoma
    (¢¡annular scotoma) °í¸®¾ÏÁ¡
  • scotoma
    ¾ÏÁ¡
  • scintillating scotoma
    (¢¡teichopsia) ¼¶±¤¾ÏÁ¡
  • suppression scotoma
    ¾ïÁ¦¾ÏÁ¡
  • relative acidosis
    »ó´ëÀû»êÁõ
  • relative convergence
    »ó´ë´«¸ðÀ½
  • relative afferent pupillary defect
    ºñ±³µé½Å°æµ¿°ø°á¼Õ
  • relative risk estimation
    »ó´ëÀ§ÇèµµÃßÁ¤
  • relative flatness
    »ó´ëŹÀ½
  • relative frequency
    ºñ±³ºóµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • relative accommodation
    »ó´ëÁ¶Àý(ÝïÎòðàï½).
  • relative acidosis
    »ó´ëÀû »êÁõ(ßÓÓßîÜß«ñø).
  • relative afferent pupillary defect
    »ó´ëÀû±¸½É¼ºµ¿°ø¿îµ¿Àå¾Ö
  • relative biologic effectiveness of radiation
    ¹æ»ç¼±ÀÇ»ó´ëÀû»ý¹°ÇÐÀûÈ¿°ú(Û¯ÞÒàÊ¡­ßÓÓßîÜßæÚªùÊîÜüùÍý)
  • relative biological effectiveness
    »ó´ëÀû »ý¹°ÇÐÀû È¿°ú(ßÓÓßîÜßæÚªùÊîÜüù
  • relative biological effectiveness
    »ó´ë»ý¹°ÇÐÀûÈ¿°ú
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£).
  • relative cardiac dullness
    »ó´ë½ÉŹÀ½°è(ßÓÓßãýöúëåÍ£)
  • relative centrifugal force
    ºñ¿ø½É·Â.
  • relative centrifugal force
    »ó´ë¿ø½É·Â(ßÓÓßêÀãýæ³).
  • relative convergence
    »ó´ëÆøÁÖ(ÝïÎòÜßñÍ), »ó´ë´«¸ðÀ½
  • relative dispersion
    »ó´ëºÐ»ê(ßÓÓßÝÂߤ).
  • relative divergence
    ºñ±³°³»ê(ÝïÎòËÒߤ).
  • relative dose
    ºñ±³ Á¶»ç·®
  • relative dullness
    °æÅ¹À½°è(ÌîöúëåÍ£).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • paracentral scotoma
    Á߽ɺαپÏÁ¡
  • pericecal scotoma
    ¸ÍÁ¡ÁÖÀ§¾ÏÁ¡
  • pericentral scotoma
    Áß½ÉÁÖÀ§¾ÏÁ¡
  • peripheral scotoma
    ÁÖº¯¾ÏÁ¡(ñ²Ü«äÞïÇ).
  • physiological scotoma
    »ý¸®Àû¾ÏÁ¡ (¡­äÞïÇ).
  • positive scotoma
    ¾ç¼º¾ÏÁ¡(ãùàõäÞïÇ), ÀνľÏÁ¡
  • quadrantic scotoma
    »çºÐ¸Í¾ÏÁ¡
  • ring scotoma
    °í¸®¸ð¾ç¾ÏÁ¡, À±»ó¾ÏÁ¡(ëÌßÒäÞïÇ).
  • ring scotoma
    À±»ó¾ÏÁ¡(ëÌßÒäÞïÇ)
  • scintillating scotoma
    ¼¶±¤¾ÏÁ¡
  • scotoma
    ¾ÏÁ¡(äÞïÇ).
  • suppression scotoma
    ¾ïÁ¦¾ÏÁ¡
  • first degree relative
    ÀϵîÄ£(ìéÔõöÑ).
  • haplodistinct relative
    ÀϹè¼öÀÌÁ¾°ü°è<--ģô>
  • haploidentical relative
    ÀϹè¼öµ¿Á¾°ü°è<--ģô>
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RR   1) Respiratory Rate
  2) Relative Risk; ºñ±³À§Çèµµ
    &n...
CRA central retinal artery; Chinese restaurant asthma; chronic rheumatoid arthritis; constant relative a...
GERRI geriatric evaluation by relative rating instrument
Mr relative molecular mass
PRICE protection, relative rest, ice, compression, elevation
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ROC Relative Operating Characteristic
RBAs Relative Binding Affinities
RBE Relative Biological Effect
RBE Relative Biological Effectiveness
RBE Relative Biological Efficiency
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • monocular scotoma
    ´Ü¾È ¾ÏÁ¡, ´Ü¾È¼º ¾ÏÁ¡
  • negative scotoma
    Ç㼺 ¾ÏÁ¡
    ½Ã¾ßÀÇ °ø¹éÁ¡ ¶Ç´Â °£±ØÀ¸·Î ³ªÅ¸³ª´Â ¾ÏÁ¡.
  • pericecal scotoma
    ¸ÍÁ¡ ÁÖÀ§ ¾ÏÁ¡
  • pericentral scotoma
    Á᫐ ÁÖÀ§ ¾ÏÁ¡
  • peripheral scotoma
    ÁÖº¯ ¾ÏÁ¡
    ÁÖ½ÃÁ¡¿¡¼­ ¸Ö¸® ¶³¾îÁö°í ½Ã¾ß ÁÖº¯À¸·Î ÇâÇÑ ½Ã°¢ ÀúÇÏ ºÎ.
  • positive scotoma
    ½Ç¼º ¾ÏÁ¡
    ½Ã¾ß¿¡¼­ ¾îµÎ¿î Á¡À¸·Î ³ªÅ¸³ª´Â °÷.
  • quadrantic scotoma
    »çºÐ ¸Í¾ÏÁ¡
  • scotoma
    ¾ÏÁ¡
    1. ½Ã¾ß ³»¿¡¼­ ½Ã°¢ÀÌ ¾ø¾îÁö°Å³ª ¾àÇØÁö´Â °Ý¸®µÈ ºÎÀ§·Î¼­ ´Ù¾çÇÑ Å©±â¿Í ÇüŸ¦ °¡Áø´Ù. 2. ½Ã¾ß ³»¿¡ ÀÖ´Â ½Ã°¢ÀÌ ÀúÇÏµÈ ºÎºÐÀ¸·Î¼­ ¾à°£ ÀúÇÏµÈ ºÎºÐ ¶Ç´Â Á¤»ó ½Ã¾ßÀÇ ºÎºÐÀ¸·Î µÑ·¯½Î¿© ÀÖ´Ù. 3. Á¤½ÅÀû ¾ÏÁ¡
  • Seidel's scotoma
    ÀÚÀ̵¨ ¾ÏÁ¡
    ±ÃÇü ¾ÏÁ¡ÀÌ ´õ¿í ¹ß´ÞµÈ °ÍÀ¸·Î¼­, 1´Ü ¶Ç´Â ¾ç´ÜÀÌ ¿¬ÀåµÇ³ª, ¿¬ÀåÀÇ ¿ä¸éÀº ¾ðÁ¦³ª ÁÖ½ÃÁ¡À» ÇâÇÑ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
relative sensitivity The sensitivity of a medical screening test as determined by comparison with the same type of test; e.g., sensitivity of a new serological test relative to sensitivity of an established serological test.
(05 Mar 2000)
relative specificity The specificity of a medical screening test as determined by comparison with the same type of test (e.g., specificity of a new serological test relative to specificity of an established serological test).
(05 Mar 2000)
relative value scales Coded listings of physician or other professional services using units that indicate the relative value of the various services they perform. They take into account time, skill, and overhead cost required for each service, but generally do not consider the relative cost-effectiveness. Appropriate conversion factors can be used to translate the abstract units of the relative value scales into dollar fees for each service based on work expended, practice costs, and training costs.
(12 Dec 1998)
relative viscosity The ratio of the viscosity of a solution or dispersion to the viscosity of the solvent or continuous phase.
(05 Mar 2000)
5-year relative survival rate <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer.
(16 Dec 1997)
absolute scotoma A scotoma in which there is no perception of light.
(05 Mar 2000)
annular scotoma A circular scotoma surrounding the centre of the field of vision.
See: ring scotoma.
(05 Mar 2000)
arcuate scotoma A scotoma extending from the blind spot and arching into the nasal field following the lines of retinal nerve fibres.
(05 Mar 2000)
Bjerrum's scotoma A comet-shaped scotoma, occurring in glaucoma, attached at the temporal end to the blind spot or separated from it by a narrow gap; the defect widens as it extends above and nasally curves around the fixation spot, and then extends downward to end exactly at the nasal horizontal meridian.
Synonym: Bjerrum's sign, sickle scotoma.
(05 Mar 2000)
caecocentral scotoma A scotoma involving the optic disk area (blind spot) and the papillomacular fibres; there are three forms: 1) the caecocentral defect which extends from the blind spot toward or into the fixation area; 2) angioscotoma; 3) glaucomatous nerve-fibre bundle scotoma, due to involvement of nerve-fibre bundles at the edge of the optic disk.
See: Bjerrum's scotoma, Ronne's nasal step.
(05 Mar 2000)
paracentral scotoma A scotoma adjacent to the fixation point.
(05 Mar 2000)
glaucomatous nerve-fibre bundle scotoma See: caecocentral scotoma.
(05 Mar 2000)
central scotoma A scotoma involving the fixation point.
(05 Mar 2000)
mental scotoma Absence of insight into, or inability to comprehend, items relative to a subject whose content is highly emotional to the individual.
Synonym: blind spot.
(05 Mar 2000)
pericentral scotoma A scotoma that surrounds the fixation point more or less symmetrically.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á